2017 Fiscal Year Final Research Report
Combination of Immune checkpoint inhibitors and vaccine in glioma stem cell
| Project/Area Number |
15K10327
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松田 真秀 筑波大学, 医学医療系, 講師 (30614333)
坪井 康次 筑波大学, 医学医療系, 教授 (90188615)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | glioma / immunotherapy / immune checkpoint / glioma stem cell |
|---|
| Outline of Final Research Achievements |
This study was designed to clarify the change of the molecular expression, including programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), on the initial and secondary resected glioblastoma (GBM) specimens and to address the influence of these expressions for patient outcome after second surgery of glioblastoma. We investigated 16 GBM patients treated with radiotherapy and temozolomide. Four patients who were treated with immunotherapy using autologous formalin-fixed tumor vaccine were enrolled. Patients with high PD-1 expression of secondary specimen had bad prognosis after secondary resection. Similar result was seen also in PD-L1 expression. PD-1/PD-L1 pathway may be associated with patient outcome after second surgery of glioblastoma. Next, vitro and vivo study using induced murine glioma stem cell showed chemodrug and/or interferon gumma enhanced PD-1/PD-L1 pathway.
|
| Free Research Field |
脳神経外科
|
